gossypol
Gossypol is a substance that is found in the cotton plant. It is removed from the seeds and used for medicine. Gossypol is effective as a nonhormonal male contraceptive; however, it has been documented to have irreversible effects on male fertility. Gossypol is reported to exhibit antioxidant, anticancer, antivirus, antiparasitic, and antimicrobial properties and lower plasma cholesterol. Nausea, emesis, anorexia, diarrhea, altered taste sensation, small intestine obstruction, and fatigue have been recorded in clinical trials as adverse reactions. Large amounts of gossypol can decrease potassium levels in the body. Low potassium levels can increase the side effects of digoxin. — NCATS
Clinical trial activity
17 trials · 11 clinical orgs · 0 marketing orgs
Earliest trial started Nov 1, 2005 (NCT00275431)
Timeline
Indications
Studied for
- Adrenocortical Carcinoma · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Esophageal Neoplasms · Phase 1/Phase 2
- Glioblastoma · Phase 2
- Laryngeal Neoplasms · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Pregnancy · Phase 3
- Prostatic Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
SMILES
CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C3=C(O)C4=C(C=C3C)C(C(C)C)=C(O)C(O)=C4C=O- Mol. weight
- 518.5544 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS8DY2X8LXW4 ↗
- ChEMBLCHEMBL51483 ↗
Also known as
- at-101
- at-101
- at101 cpd
- gosipol
- gosspyl acetate
- gossypol
- gossypol
- gossypol
- gossypol
- gossypol
- gossypol acetic acid
- gossypol acetic acid
- gossypol dipotassium
- gossypol potassium
- gossypol sodium
- gossypol sodium
- gossypol sodium
- gossypol sodium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07260162 | Phase 1 | Feb 28, 2026 | Institut de Cancerologie de l'Ouest Paul Papin |
| NCT07285395 | Phase 1 | Nov 12, 2025 | Xuzhou Medical University |
| NCT06133088 | Phase 2 | Aug 1, 2023 | Chinese Academy of Medical Sciences |
| NCT01977209 | Phase 3 | Sep 1, 2013 | People's Liberation Army of China |
| NCT01633541 | Phase 2 | Mar 1, 2012 | University of Michigan |
| NCT01285635 | Phase 2 | Jun 1, 2010 | University of Michigan |
| NCT00934076 | Phase 1 | Feb 1, 2010 | Ascenta Therapeutics, University of Alabama, Birmingham |
| NCT00988169 | Phase 2 | Sep 1, 2009 | Ascenta Therapeutics, Cornell University |
| NCT00666666 | Phase 2 | Jul 1, 2009 | National Cancer Institute (NCI), Rutgers University |
| NCT00571675 | Phase 2 | Oct 1, 2007 | Ascenta Therapeutics |
| NCT00544960 | Phase 2 | Sep 1, 2007 | Ascenta Therapeutics |
| NCT00561197 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2007 | Ascenta Therapeutics |
| NCT00397293 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2006 | Ascenta Therapeutics |
| NCT00440388 | Phase 2 | Oct 1, 2006 | Ascenta Therapeutics |
| NCT00286780 | Phase 2 | Jan 1, 2006 | Ascenta Therapeutics, University of California, San Diego |
| NCT00286806 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2005 | Ascenta Therapeutics |
| NCT00275431 | Phase 2 | Nov 1, 2005 | Ascenta Therapeutics |
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ascenta Therapeutics | For profit | 10 | 8 | 2 | 2005 |
| University of Michigan | Academic/Hospital | 2 | 2 | 1 | 2010 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Institut de Cancerologie de l'Ouest Paul Papin | Academic/Hospital | 1 | 1 | 1 | 2026 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2009 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2013 |
| Rutgers University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Xuzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |